Holen Sie sich die Stockscreener-App
571.51
2.55%
-15.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$586.64
Offen:
$580
24-Stunden-Volumen:
124.20K
Relative Volume:
0.19
Marktkapitalisierung:
$45.02B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
42.05
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
-2.24%
1M Leistung:
+1.43%
6M Leistung:
-7.38%
1J Leistung:
-12.36%
1-Tages-Spanne:
$568.22
$584.15
1-Wochen-Bereich:
$568.22
$602.00
52-Wochen-Spanne:
$518.55
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
571.50 | 46.22B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
601.15 | 223.70B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
206.22 | 145.83B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
316.01 | 45.08B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
148.81 | 42.22B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - marketwatch.com
IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment - marketscreener.com
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test - eagletribune.com
Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating - marketscreener.com
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - marketwatch.com
NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc (HAM:IX1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Stock Price & 30 Year Financial Data - GuruFocus
IDEXX Laboratories (HAM:IX1) Other Operating Expense : €0 Mil (TTM As of Jun. 2026) - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Competitors 2026 - GuruFocus
IDEXX Laboratories Inc (HAM:IX1) Stock News, Headlines & Updates - GuruFocus
Who's Buying or Selling IDEXX Laboratories Inc (HAM:IX1) Stock Today? - GuruFocus
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEXX Labs posts 9% organic growth, raises EPS forecast, driven by global diagnostic expansion. - pluang.com
IDEXX Laboratories: Worth The Premium (NASDAQ:IDXX) - Seeking Alpha
IDEXX Laboratories, Inc. $IDXX Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Assenagon Asset Management S.A. Boosts Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Aurora Investment Managers LLC. Makes New Investment in IDEXX Laboratories, Inc. $IDXX - MarketBeat
What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate? - Moomoo
Janus Henderson Group PLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter. - TIKR.com
IDEXX Laboratories (NASDAQ:IDXX) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
IDEXX Labs Is Maintained at Neutral by UBS - Moomoo
IDEXX Labs Is Maintained at Neutral by Citigroup - Moomoo
Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 - Moomoo
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670 - Moomoo
Citi Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670 - Moomoo
IDEXX Laboratories Inc (HAM:IX1) Stock Earnings Transcripts - GuruFocus
IDEXX (IDXX) Stock Rewards Margin Strength And Recurring Diagnostics Growth - Sahm
IDEXX Laboratories Inc (IDXX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... - finance.yahoo.com
IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary - TradingView
IDEXX Laboratories (NASDAQ: IDXX) lifts Q2 2026 profit and cash flow - Stock Titan
IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside - TradingView
Idexx Laboratories, Inc. Updates Earnings Guidance for 2026 - marketscreener.com
IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ) - Seeking Alpha
IDEXX Laboratories Q2 Earnings Call Highlights - MarketBeat
Why Is IDEXX Laboratories Stock Gaining Tuesday? - benzinga.com
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - Moomoo
Earnings call transcript: IDEXX tops Q2 2026 forecasts and lifts outlook - Investing.com
IDEXX Q2 earnings jump 18%, beating expectations - Mainebiz
IDEXX Laboratories' Q2 Earnings, Revenue Increase; 2026 Outlook Updated - marketscreener.com
IDEXX Laboratories Q2 2026 Earnings Call Transcript - benzinga.com
IDEXX Laboratories Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 IDEXX Laboratories Inc Earnings Call Transcript - GuruFocus
IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook - finance.yahoo.com
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates - finance.yahoo.com
IDEXX Labs stock rises nearly 4% on earnings beat and raised guidance - Investing.com
Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q2 Revenue $1.22B, vs. FactSet Est of $1.20B - marketscreener.com
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):